ArticleBMC oral health2026
Color and translucency changes induced by try-in media in bleach-shade CAD/CAM ceramic discs: an in-vitro study.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study evaluated the optical influence of try-in media (distilled water, glycerin, and commercial try-in pastes) on ultrathin (0.5-mm) CAD/CAM bleach-shade ceramic discs, focusing on CIEDE2000 color difference (ΔE₀₀), translucency parameter (TP₀₀; ΔE₀₀ between white- and black-backed measurements), and device-reported shade outputs across different ceramic systems.
methodsForty-four 0.5-mm CAD/CAM ceramic discs were fabricated from Celtra Duo (BL2-LT, BL3-LT), VITA Suprinity (0M1-HT), and VITA Enamic (0M1-HT). Each specimen was measured over standardized white and black backgrounds using distilled water, glycerin, eight commercial try-in pastes, or no medium (control). Lab* values and VITA Classic/3D-Master shade outputs were recorded with a dental spectrophotometer under D65/2° conditions; a custom jig standardized specimen positioning and probe angulation. Repeated measurements (n = 5) were analyzed using linear mixed-effects models. Clinical interpretation used ΔE₀₀ perceptibility/acceptability (≈ 0.8/1.8) and translucency thresholds (TPT₀₀=0.62; TAT₀₀=2.62).
resultsRelative to the no-media condition, both water and glycerin produced large, clinically perceptible color shifts across all ceramics (mean ΔE₀₀ ≈ 3.2–5.6; p < 0.001), while direct water–glycerin differences were smaller (≈ 0.7–1.6). Translucency responses were material dependent: Celtra groups showed minimal ΔTP₀₀ relative to glycerin (typically |ΔTP₀₀| ≤ ~0.3), Suprinity showed a modest reduction ( ≈ − 1 to − 2), and Enamic exhibited pronounced translucency loss ( ≈ − 5 to − 7), frequently exceeding translucency acceptability (|ΔTP₀₀| ≥ 2.62). Only selected Celtra BL2/BL3 conditions with translucent/light try-in pastes approached ΔE₀₀ acceptability (≤ 1.8) on white backgrounds. Device-reported shade agreement sometimes masked clinically unacceptable differences: 11% of 3D-Master “matches” and 28% of Classic “matches” still corresponded to ΔE₀₀ > 1.8, particularly over black backgrounds.
conclusionsTry-in media are not optically neutral for ultrathin bleach-shade ceramics. Water and glycerin both produced clinically visible color changes, and translucency effects depended strongly on ceramic microstructure, with Enamic showing clinically unacceptable masking. Clinically, shade selection should not rely on device-reported shade matches alone; verification with appropriate try-in media and evaluation over both white and dark conditions using continuous metrics (ΔE₀₀, TP₀₀/ΔTP₀₀) is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.